Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Argentiero A, De Summa S, Di Fonte R, Iacobazzi RM, Porcelli L, Da Vià M, Brunetti O, Azzariti A, Silvestris N, Solimando AG. Argentiero A, et al. Among authors: brunetti o. Cancers (Basel). 2019 Jul 4;11(7):942. doi: 10.3390/cancers11070942. Cancers (Basel). 2019. PMID: 31277479 Free PMC article.
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy.
Mangia A, Caldarola L, Dell'Endice S, Scarpi E, Saragoni L, Monti M, Santini D, Brunetti O, Simone G, Silvestris N. Mangia A, et al. Among authors: brunetti o. Cancer Biol Ther. 2015;16(8):1140-7. doi: 10.1080/15384047.2015.1056414. Epub 2015 Jun 30. Cancer Biol Ther. 2015. PMID: 26126066 Free PMC article.
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V, Angarano G, Brunetti O, Guarini A, Pisconti S, Lorusso V, Silvestris N. Gnoni A, et al. Among authors: brunetti o. Expert Opin Ther Targets. 2015;19(12):1623-35. doi: 10.1517/14728222.2015.1071354. Epub 2015 Jul 27. Expert Opin Ther Targets. 2015. PMID: 26212068 Review.
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, Partelli S, Falconi M, Scarpa A, Brunetti O, Lorusso V, Santini D, Morganti A, Valentini V, Cascinu S. Silvestris N, et al. Among authors: brunetti o. Crit Rev Oncol Hematol. 2016 Feb;98:309-24. doi: 10.1016/j.critrevonc.2015.11.016. Epub 2015 Nov 23. Crit Rev Oncol Hematol. 2016. PMID: 26653573 Review.
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy.
Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N, Bianconi M, Giampieri R, Valgiusti M, Brunetti O, Bittoni A, Andrikou K, Lai E, Dessì A, Cascinu S, Scartozzi M. Faloppi L, et al. Among authors: brunetti o. Sci Rep. 2016 Apr 11;6:24136. doi: 10.1038/srep24136. Sci Rep. 2016. PMID: 27063994 Free PMC article.
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, Scartozzi M. Puzzoni M, et al. Among authors: brunetti o. Target Oncol. 2016 Oct;11(5):593-603. doi: 10.1007/s11523-016-0437-6. Target Oncol. 2016. PMID: 27184491 Review.
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
Longo V, Brunetti O, Gnoni A, Cascinu S, Gasparini G, Lorusso V, Ribatti D, Silvestris N. Longo V, et al. Among authors: brunetti o. Oncotarget. 2016 Sep 6;7(36):58649-58658. doi: 10.18632/oncotarget.10765. Oncotarget. 2016. PMID: 27462915 Free PMC article. Review.
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Azzariti A, et al. Among authors: brunetti o. World J Gastroenterol. 2016 Jul 21;22(27):6287-95. doi: 10.3748/wjg.v22.i27.6287. World J Gastroenterol. 2016. PMID: 27468218 Free PMC article.
166 results